Resources from the same session
1739 - 18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: a study to identify the optimal dosing schedule of neoadjuvant (neoadj) Ipilimumab (IPI) + Nivolumab (NIVO) in stage III melanoma
Presenter: Elisa Rozeman
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract
Poster Discussion – Melanoma and other skin tumours - Invited Discussant 1312PD and one LBA TBC
Presenter: Paolo Ascierto
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Slides
Webcast
Poster Discussion – Melanoma and other skin tumours - Invited Discussant 3 LBAs TBC
Presenter: Ana Arance
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Slides
Webcast
Poster Discussion – Melanoma and other skin tumours - Invited Discussant 1314PD, 1315PD, and 1316PD
Presenter: Salvador Martin Algarra
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Slides
Webcast